Patient characteristics
| Characteristic . | Value . |
|---|---|
| No. of patients | 90 |
| Median age, y (range) | 54 (19.1-71.2) |
| Sex | |
| Male | 45 |
| Female | 45 |
| Diagnosis | |
| De novo AML | 39 |
| AML secondary to MDS | 30 |
| AML secondary to other malignancies | 10 |
| MDS | 8 |
| MDS secondary to other malignancies | 3 |
| Risk stratification according to cytogenetics | |
| Good | 3 |
| High | 49 |
| Standard | 35 |
| Unknown | 3 |
| Stage at transplantation | |
| Untreated | 16 |
| Primary induction failure | 28 |
| First CR | 13 |
| Second CR | 4 |
| First relapse after CR | 24 |
| Second relapse after CR | 3 |
| Third relapse after CR | 2 |
| Donor type | |
| MRD | 24 |
| MMRD | 1 |
| MUD | 45 |
| MMUD | 20 |
| CMV status | |
| Patient−/donor− | 25 |
| Patient+/donor− | 18 |
| Patient−/donor+ | 8 |
| Patient+/donor+ | 36 |
| NE | 3 |
| Stem cell source | |
| PBSCs | 81/1* |
| Bone marrow | 8/1* |
| GVHD | |
| Acute | 39 |
| Chronic | 19 |
| Chemotherapy cycles, no. (range) | 1 (0-4) |
| Median marrow blasts, % (range) | 10 (0-90) |
| Median peripheral blasts, per μL (range) | 0 (0-34.560) |
| Median white blood count, per μL (range) | 2.85 (200-35.000) |
| Median follow-up, d (range) | 327 (10-1161) |
| Characteristic . | Value . |
|---|---|
| No. of patients | 90 |
| Median age, y (range) | 54 (19.1-71.2) |
| Sex | |
| Male | 45 |
| Female | 45 |
| Diagnosis | |
| De novo AML | 39 |
| AML secondary to MDS | 30 |
| AML secondary to other malignancies | 10 |
| MDS | 8 |
| MDS secondary to other malignancies | 3 |
| Risk stratification according to cytogenetics | |
| Good | 3 |
| High | 49 |
| Standard | 35 |
| Unknown | 3 |
| Stage at transplantation | |
| Untreated | 16 |
| Primary induction failure | 28 |
| First CR | 13 |
| Second CR | 4 |
| First relapse after CR | 24 |
| Second relapse after CR | 3 |
| Third relapse after CR | 2 |
| Donor type | |
| MRD | 24 |
| MMRD | 1 |
| MUD | 45 |
| MMUD | 20 |
| CMV status | |
| Patient−/donor− | 25 |
| Patient+/donor− | 18 |
| Patient−/donor+ | 8 |
| Patient+/donor+ | 36 |
| NE | 3 |
| Stem cell source | |
| PBSCs | 81/1* |
| Bone marrow | 8/1* |
| GVHD | |
| Acute | 39 |
| Chronic | 19 |
| Chemotherapy cycles, no. (range) | 1 (0-4) |
| Median marrow blasts, % (range) | 10 (0-90) |
| Median peripheral blasts, per μL (range) | 0 (0-34.560) |
| Median white blood count, per μL (range) | 2.85 (200-35.000) |
| Median follow-up, d (range) | 327 (10-1161) |
Data are numbers unless otherwise defined.
AML indicates acute myeloid leukemia; MDS, myelodysplastic syndrome; CR, complete remission; MRD, matched related donor; MMRD, mismatched related donor; MUD, matched unrelated donor; MMUD, mismatched unrelated donor; CMV, cytomegalovirus; NE, PBSCs, peripheral blood stem cells; and GVHD, graft-versus-host disease.
One patient received stem cells from both PBSCs and bone marrow.